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Abstract
Cancer poses a serious health problem in society and is increasingly surpassing cardiovascular disease as the
leading cause of mortality in the United States. Current therapeutic strategies for cancer are extreme and harsh
to patients and often have limited success; the danger of cancer is intensified as it metastasizes to secondary
locations such as lung, bone, and liver, posing a dire threat to patient treatment and survival. Hedgehog signaling
is an important pathway for normal development. Initially identified in Drosophila, the vertebrate and mammalian
equivalent of the pathway has been studied extensively for its role in cancer development and progression. As
this pathway regulates key target genes involved in development, its action also allows for the modulation of
the microenvironment to prepare a tumor-suitable niche by manipulating tumor cell growth, differentiation, and
immune regulation, thus creating an enabling environment for progression and metastasis. In this review, we will
summarize recent scientific discoveries reporting the impact of the Hedgehog signaling pathway on the tumor
initiation process and metastatic cascade, shedding light on the ability of the tumor to take over a mechanism
crucially intended for development and normal function.
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Background
In order for tumor initiation and metastasis to occur,
tumors usurp several signaling pathways that contrib-
ute to normal growth and tissue repair. The normal
development of mammalian embryos involves multiple
signaling pathways that regulate cell proliferation,
survival, and differentiation such as the Hedgehog
(Hh) [1], Wnt [2], TGF-β [3], and Notch [4] signaling
pathways. When cells become cancerous, they recruit
cellular machinery that typically promotes regular
physiological functions such as tissue growth, survival,
vascularization, and healing. Hh signaling is involved
early in embryogenesis where it promotes cell growth,
differentiation, tissue patterning, and vascularization;
all of which are aspects that tumor cells employ in
order to thrive and metastasize. In adult tissue, the
activation of the Hh pathway maintains homeostasis
by being limited to stem cell subsets that undergo
rapid turnover and modulate tissue repair [5] such as
the nervous system [6], skin [7] and intestines [8].
The Hh signaling pathway becomes aberrantly acti-
vated through the overexpression of Hh ligands, loss-
of-function of the receptor, or dysregulation of the
transcription factors. All these aberrations have been
implicated in initiation and progression of multiple
cancer types including breast, prostate, hepatocellular,
pancreatic, and brain cancers. As such, the pathway
has been intensely investigated for the development
of inhibitors for therapeutic benefit in human cancers.
In this review, we summarize recent advances on the
influence of Hh signaling on tumor initiation, pro-
gression, and metastasis through modulating a multi-
tude of processes that are considered signature
features of cancer as were characterized by Hanahan
and Weinberg [9, 10].
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The mammalian Hh signaling pathway
Hh signaling involves a complex network of molecules.
The canonical Hh signaling pathway can be initiated by
three ligands: Desert hedgehog (DHH), Indian hedgehog
(IHH) or Sonic hedgehog (SHH). These bind to the 12-
pass transmembrane protein receptors Patched1 (PTCH1)
and Patched 2 (PTCH2), which were initially found to
form a complex with single pass co-receptor proteins:
Cell adhesion molecule-related/downregulated by on-
cogenes (CDON) and Brother of Cdo (BOC) [11, 12].
The glycosylphosphatidylinisotol (GPI) anchor receptor
Growth arrest-specific 1(GAS1) completes this co-receptor
complex [1]. Once ligand binding occurs, PTCH receptors
relieve their inhibitory action on Smoothened (SMO),
a 7-pass transmembrane G-protein coupled signal trans-
duction molecule, which then activates a signaling cascade
resulting in the translocation of the glioma associated
oncogene homolog (GLI) transcription factors to the
nucleus. Emerging evidence suggests Hh ligand binding to
each of the co-receptors, not only to PTCH as initially
thought, is obligatory for the activation of the Hh signaling
cascade [13]. In the absence of the ligand, SMO is nor-
mally localized in vesicles. When the pathway is activated,
SMO localizes to the primary cilium on the cell mem-
brane (Fig. 1). There are three GLI transcription factors:
GLI1 that exclusively acts as a transcription activator,
GLI2 and GLI3 that can act either as repressors or
activators, in a context-dependent manner [14]. In their
full-length form, all three transcription factors can be acti-
vators. GLIs 2 and 3 however can be processed into their
truncated repressive form. Protein kinase A (PKA) is the
molecule responsible for the activation or repression of
the GLI proteins depending on the specific sites of protein
it phosphorylates [15]. GLI3 acts as the main repressor of
the pathway in the absence of Hh ligands, whereas, in
their presence, the main activator GLI2 leads to the activa-
tion of GLI1, promoting its translocation into the nucleus
where it initiates the transcription of downstream target
genes.
In the nucleus, the GLI transcription factors bind DNA
and modulate the transcription of a multitude of genes
including Fox, Myc, and cyclin D among others that are
involved in tissue development, differentiation, epithelial-
mesenchymal transition (EMT), and stem cell mainten-
ance. Recently, GLI1 protein transcript was found to
undergo alternative splicing establishing two isoforms
with different functions: an N-terminal deletion and a
truncated GLI1 variant [16]. The truncated isoform is
found only in cancer tissue and promotes transcription of
additional target genes that create a pro-tumorigenic
environment for tumor cells to expand.
Although the Hh signaling pathway is normally acti-
vated upon ligand binding to the receptor, multiple
mechanisms have been involved in enhancing GLI pro-
tein activity in the absence of Hh ligands. In breast
cancer, TGF-β signaling was shown to activate GLI2 tar-
get genes culminating in enhanced bone metastasis [17].
In basal cell carcinoma (BCC), mutated PTCH1 expres-
sion prevented cellular response to cell cycle checkpoint
cyclin B1 and promoted GLI activation [18]. In Burkitt
Fig. 1 In the absence of Hh ligands, the PTCH receptor sequesters SMO in a cytoplasmic vesicle. GLI proteins are bound in a complex in the
cytoplasm with negative regulators SUFU and KIF7, which target the GLI proteins for phosphorylation by PKA, CK1, and GSK3β inducing the
repressive form of GLI proteins. Upon DHH, IHH, or SHH binding to PTCH, PTCH relieves its inhibition on SMO, which then translocates to the
primary cilium of the cell and mediates the dissociation of GLI proteins from SUFU and KIF7, allowing localization of GLI proteins to the nucleus
where they bind DNA and regulate the transcription of their target genes
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lymphoma, oncogene c-MYC was found to regulate
GLI1 expression independently of SMO, PTCH or the
presence of Hh ligands [19]. Furthermore, several re-
ports in a pancreatic cancer model confirm that Hh
pathway is activated in a paracrine manner [20].
Other signaling pathways have also been demon-
strated to directly activate GLI proteins in a variety of
cancer types such as PI3K/AKT [21–23] and RAS/
ERK [24, 25] signaling have also been demonstrated
to directly activate GLI proteins. Therefore, it is clear
that the activation of GLI proteins and the transcrip-
tion of their downstream target genes are not
restricted to classical Hh signaling which occurs
through ligand binding to the PTCH receptor and co-
receptors, but can proceed non-classically as a result
of crosstalk between diverse intracellular signaling
networks.
Hh pathway mechanisms of activation
The Hh signaling pathway must be strictly controlled
in order to prevent aberrant activation. The Hh sig-
naling pathway can be activated by four different
mechanisms. And though the downstream effects of
Hh activation are ultimately proliferation and differ-
entiation, it is notable that its mode of activation dif-
fers depending on the cancer type [26, 27].
The Hh signaling pathway can be activated classic-
ally through ligand binding or non-classically in the
absence of the ligand [28], both of which are GLI-
dependent. Canonical, classical activation of Hh sig-
naling involves the presence of Hh ligands, which
initiate the signaling cascade leading to GLI translocation
to the nucleus and binding DNA; this can occur as
autocrine, paracrine, or inverse paracrine activation.
Autocrine Hh signaling depends on tumor cells
secreting Hh ligands, which then act upon themselves
in a positive feedback loop; this mode of activation is
found in breast cancer [29], non-small cell lung cancer
[30], and colorectal cancer [31]. Paracrine signaling, on
the other hand, comprises of tumor cells secreting Hh
ligands that bind receptors on the surrounding stroma
thus activating stromal Hh signaling; this is mainly found
in pancreatic cancers [32, 33]. In inverse paracrine Hh
activation, however, stromal cells produce the Hh ligands,
which bind and activate the signaling pathway in tumor
cells; multiple myeloma [34] and lymphoma [35] display
this mode of activation.
The non-classical mode of activation is, as men-
tioned above, independent of Hh ligand presence,
which occurs irrespective of PTCH receptors loss of
function or gain of function of SMO; this mode is
found in BCC [36], and can occur in breast cancer
[37]. Alternative signaling pathways such as PI3K
[21–23] and RAS [24, 25] signaling are also capable
of activating non-classical Hh signaling by direct
binding and activation of the GLI proteins. The path-
way can also be activated non-canonically, which is
independent of GLI activation [38]. Non-canonical Hh
signaling is the result of upregulation of genes in-
volved in the initial steps of the pathway such as
SMO upregulation by SDF-1 in pancreatic cancer
[39]. Hh ligand and SMO are also capable of inducing
angiogenesis and reducing apoptosis in epithelial cells
[40] by directly interacting with GTPase RhoA in the
absence of GLI. Additionally, mutations that result in
overproduction of Hh ligands in breast cancer [41]
and BCC [42], loss of PTCH receptor function in
BCC [43] and gastric cancer [44], as well as upregula-
tion of SMO activity in pancreatic cancer stroma [45]
and BCC [46] can lead to constitutively activated Hh
signaling [47].
Targeting the Hh pathway components
The first identified naturally occurring Hh blocker is
cyclopamine, which causes developmental abnormal-
ities in animals. The Beachy group first reported the
inhibitory effect of cyclopamine on Hh signaling to
occur by directly binding and inhibiting SMO [48].
However, the weak potency of the natural chemical
elicited the need to develop modified chemical deriva-
tives, which spurred the development of KAAD-
cyclopamine [49]. Aside from SMO inhibition, several
other Hh inhibitors have been identified for use in
basic research. Small molecule inhibitors, GANT-58
and GANT-61 prevent GLI proteins from binding to
DNA in the nucleus, thus blocking their transcrip-
tional activity [50]. Additionally, the monoclonal anti-
body 5E1 is used in research to block SHH, IHH, and
DHH binding to the PTCH1 receptor thereby, block-
ing the classical Hh signaling pathway [51].
The first FDA approved Hh inhibitor for clinical
use is vismodegib (Genentech) marketed as Erivedge
[52]. Approved in 2012, vismodegib targets SMO and
is used to treat BCC patients, with promising results
in other cancer types. Another SMO antagonist eris-
modegib (Novartis), also known as sonidegib and
LDE-225, was recently FDA approved for treating
BCC patients with recurrent disease or for those do
not qualify for radiation or surgical removal [53].
Currently, there are several Hh inhibitors employed
in clinical trials for multiple types of cancers. For
example, sonidegib is being tested on patients with
advanced hepatocellular carcinoma [54] and in com-
bination with Paclitaxel in patients with recurring
ovarian cancer [55], Bortezomib (a proteasome inhibi-
tor) in patients with multiple myeloma (MM) in a
recently closed trial [56], and with Docetaxel for pa-
tients with triple negative breast cancer [57]. Another
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SMO antagonist glasdegib, also known as PF-04449913,
is being tested in patients with acute myeloid leukemia
(AML) [58] and in combination with nucleoside ana-
log Azacitidine for other hematologic malignancies
such as chronic myelomonocytic leukemia [59]. Al-
though Hh inhibitors have been mostly promising,
several clinical trials have ended in failure. In 2012,
Infinity Pharmaceuticals terminated a phase II clinical
trial in pancreatic cancer patients employing SMO in-
hibitor saridegib in combination with gemcitabine as
patients treated with this combination had an overall
lower survival than the placebo treated group [60].
Another clinical trial in metastatic pancreatic cancer
testing the combination of vismodegib with gemcita-
bine showed no significant differences in Hh pathway
expression in the combination vs gemcitabine alone
treatment [61]. In metastatic colorectal cancer, pa-
tients treated with vismodegib in combination with
bevacizumab and FOLFOX or FOLFIRI (standard of
care for metastatic colorectal cancer), did not add sig-
nificant benefits to patient survival [62] Although Hh
inhibitors effectively treat BCC, for which they were
initially approved, their usage in treating other tumor
types potentially carries significant risks, therefore,
the mechanisms of Hh signaling should be critically
evaluated in specific tumor types prior to commen-
cing Hh inhibitor clinical trials in patients.
In the ensuing paragraphs, we will summarize re-
cent scientific discoveries reporting the impact of the
Hh signaling pathway on the tumor initiation process
and metastatic cascade, shedding light on the ability
of tumors to takeover a mechanism crucially intended
for development and normal function. We have spe-
cifically focused on the recent advances and know-
ledge garnered to address novel tumor properties that
pertain to creating a favorable microenvironment
known as the updated hallmarks of cancer as de-
scribed by Hanahan and Weinberg (Fig. 2).
Sustained proliferative signaling
The most pronounced characteristic of cancer is the
unrestricted proliferation of cells. As the main func-
tion of Hh signaling is to promote fetal development
and patterning, it is expected that signaling through
the pathway would upregulate genes involved in cellu-
lar proliferation and survival, a function that tumors
manipulate. Not only does Hh signaling promote the
over-proliferation of cancer cells themselves, but it
Fig. 2 The Hedgehog signaling pathway plays an important role in tumor initiation and metastasis through profoundly altering the ten hallmarks
of cancer
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also modulates cells found in the local microenviron-
ment. Wilkinson and colleagues found that human
prostate cancer associated fibroblasts (CAFs) have the
capability of forming primary cilia; this was associated
with upregulation of canonical Hh signaling [63].
Additionally, engraftment of non-malignant prostate
cells bearing constitutively active Smo into mice
resulted in increased levels of cellular proliferation by
the prostate cells. The enhanced proliferation of cells
was attributed to the expression of increased fibro-
blast growth factor 5 (Fgf5) and insulin-like growth
factor-binding protein 6 (Igfbp6), both of which are
growth factors responsible for cell growth and sur-
vival. Hh signaling is recognized to be upregulated in
pancreatic cancer stromal tissue. In pancreatic cancer
cells lentiviral-mediated SMO suppression reduced
cell proliferation and colony formation in vitro [64].
In vivo, SMO-silenced cells formed smaller xenograft
tumors in nude mice. Using a parallel but complementary
approach Singh et al. reported that treatment with SMO
inhibitor vismodegib of human pancreatic cancer stem
cells resulted in decreased cell viability and spheroid for-
mation capability [65]. Though paracrine Hh signaling has
long been associated with PDAC, Lee et al. report that Hh
inhibition in pancreatic stroma results in increased tumor
size and reduced overall animal survival [66]. In medullo-
blastoma (MB), Shh promotes hyperplasia of cerebellar
granule precursor cells through the activation of HDACs,
which in turn permit chromatin activity that leads to a
sustained proliferative signal. Inhibiting the activity of
HDACs with trichostatin A abrogated Shh-driven prolifer-
ation [67]. This study brought to light an interesting and
relevant connection of activated Hh signaling with the
chromatin-remodeling program. Furthermore, dysregu-
lated Hh signaling upregulates levels of Cyclin D1 which
directly leads to excessive proliferation as Cyclin D1 facili-
tates the ability of cells to bypass the mitotic cellular
checkmarks leading to MB formation [68] and neuroblast-
oma [69]. As will be discussed in greater detail later, it was
recently found that Hh signaling upregulates telomeric
activity by increasing TERT expression in glioblastoma
multiforme (GBM) [70]. The sustained proliferative signal
leading to cancer development results from a combination
of conditions such as upregulated growth factors and
growth receptors, replicative immortality, and growth
suppression evasion; those aspects will be discussed as
their own specific hallmarks. The involvement of Hh
signaling in proliferation, either pathologically or develop-
mentally is evident from years of cancer research making
Hh signaling a vital tool for cancers to employ.
Replicative immortality
Cancer by definition is the uncontrolled replication of
cells. Cancers successfully employ telomeric activation
to maintain maximum replication; this is supported by the
Hh pathway’s ability to upregulate telomerase activity. As
the normal function of Hh signaling pathway is to promote
embryonic development, it essentially controls and influ-
ences cellular division allowing its implication in various
cancers as a driver for telomerase activity. The telomerase
subunit is made up of telomerase reverse transcriptase
(TERT) and telomerase RNA component, both of which
make up the complex that drives cell replication [71].
Recently, it has been shown that GLI1 and GLI2 drive
human TERT in colon and prostate cancers as well as
GBM [70]. Blocking GLI activity by GANT-61 abrogated
the enzymatic function of TERT. In addition, whole
genome sequencing of SHH-driven MB showed a strong
association with TERT promoter mutations [72]. Such ro-
bust influence on telomere function makes Hh signaling
activation a valuable asset for tumor initiation.
Deregulated cellular energetics
It is widely accepted that tumors adapt to hypoxic envi-
ronments and survive by upregulating genes that pro-
mote anaerobic metabolism such as hypoxia-inducible
factor-1α (HIF-1α) [73]; this is known as the “Warburg
effect”. HIF-1α enables tumor cells to harness their
energy by resorting to glycolytic instead of oxidative me-
tabolism through up-regulating glucose transporters and
pyruvate dehydrogenase kinase 1 (PDK1). PDK1 blocks
the pyruvate dehydrogenase facilitated conversion of
pyruvate to glucose, instead directing its conversion into
lactate by lactate dehydrogenase A (LDHA). This leads
to an increase in lactate production and consequently,
increased glucose uptake [74]. Also, it is widely accepted
that the lack of blood perfusion in hypoxic environments
can hinder drug delivery and cause chemotherapy resist-
ance in cancer [75–77]. Hh signaling drives hypoxia re-
sponses in different cancer models. In MB, Hh signaling
is overly activated and drives glycolysis by upregulating
hexokinase 2 and pyruvate kinase M2 that cumulatively
promote lactate production [78]. Using a pyruvate kinase
inhibitor reduced Hh-driven in vitro proliferation and
in vivo MB growth. In PDAC, Hh pathway is non-
classically activated by hypoxia, bypassing Hh ligand
binding and Smo activation and directly activating Gli1
resulting in enhanced invasiveness through the induction
of MMP2 and MMP9. These effects were abrogated
upon blocking Gli1 [79, 80]. Additionally, mice with
cervical cancer xenografts that were exposed to hypoxic
conditions sustained higher levels of metastasis. When
Hh signaling was blocked with 5E1 antibody, primary
tumor growth and lymph node metastasis were reduced
[81]. Collectively, this body of evidence supports the role
for Hh signaling in promoting a tumor cell metabolism
shift aiding in solid tumor progression, invasiveness, and
therapy resistance.
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Inflammation
Cancer has long been associated with inflammatory re-
sponses [82, 83]. Inflammation in the tumor microenviron-
ment drives several processes involved in the progression
of cancer such as proliferation, EMT, angiogenesis, and
metastasis through the upregulation of several pathways
including NF-κB, TGF-β, and Hh signaling. Nucleotide-
binding oligomerization domain-containing protein 2
(NOD2) signaling in inflammatory bowel disease is
typically important for recognizing pathogenic patterns and
promotes inflammation to elicit their removal by the
immune system. NOD2 is reported to activate SHH and
upregulate GLI1, further intensifying the inflammatory
response [84]. The inhibition of Hh signaling in rats with
arthritis using Smo inhibitor cyclopamine, reduced the ex-
pression of pro-inflammatory molecules such as TNF-α,
IL-1β and IL-6 [85]. These pro-inflammatory molecules
were also reduced in a mouse hepatocellular carcinoma
model by vismodegib, which also targets Smo [86]. Patients
with chronic cholecystitis often advanced to gallbladder
carcinoma; and patients whose tumor samples expressed
high levels of GLI1 were associated with unfavorable sur-
vival outcomes. In Helicobacter pylori-driven gastritis that
progressed to gastric metaplasia, Gli1 was found to drive
myeloid cell differentiation and upregulation of IL-6, IL-1β,
and TNFα, three important cytokines for activating STAT3
signaling, the main promoter of the inflammatory response
[87]. These effects were not observed in mice expressing
mutant Gli1, directly implicating Hh signaling in gastric
cancer initiation. Also in gastric cancer, tumor derived
ligands behave as chemoattractants for macrophages that
further intensify the inflammatory cascade leading to gas-
tric cancer progression [88]. In gastric tissue specifically,
Hh signaling has to be tightly regulated as it is vitally
necessary for gastric tissue morphogenesis, however, its
uncontrolled activation can contribute to the chronic
inflammation associated with gastric cancer as mentioned
above. As such, multiple evidences clearly show that Hh
signaling is capable of promoting the inflammatory process
in the microenvironment, which facilitates cancer initiation
and progression.
Angiogenesis
The formation of new limbs as development progresses
requires the creation of blood vessels through the induc-
tion of pro-angiogenic factors such as vascular endothelial
growth factors (VEGF) and fibroblast growth factors
(FGF). Both VEGF and FGF are direct transcriptional tar-
gets of the Hh signaling pathway [89]. In an in vivo ortho-
topic hepatocellular carcinoma model, Smo inhibition
using vismodegib downregulated VEGF expression leading
to decreased blood vessel density and tumor growth [90].
In vitro however, vismodegib did not affect cell viability or
migration, which is unsurprising considering the necessary
complex physiological environment that allows for angio-
genesis. Analysis of colorectal cancer patient specimens
showed a strong positive correlation between Gli1 and
VEGF-C and its receptor VEGFR3 [91]. In breast cancer,
Hh signaling enhanced tumor angiogenesis independently
of VEGF activation. SHH-mediated GLI1 activity lead
to the transcriptional activation of the cysteine-rich an-
giogenic inducer 61 (CYR61); silencing CYR61 resulted
in reduced tumor vasculature of SHH-driven xenografts
[92]. A recent report in pancreatic cancer showed high
expression of Hh co-receptors GAS1, BOC, and CDON
in CAFs leading to larger tumor growths and increased
vascularity. Deleting the three co-receptors blocked
these tumorigenic properties and angiogenesis [93].
The implication of several members of the Hh pathway
including the ligands, the receptor, and even co-receptor
involvement convincingly demonstrates the crucial influ-
ence of Hh signaling on angiogenic changes leading to the
establishment of vasculature necessary to support the
growing tumors and facilitate metastasis.
Although the majority of published literature largely
associates Hh signaling with increased angiogenesis, sev-
eral reports have emerged in pancreatic cancer models
showing increased vascularization enhancing drug
delivery upon the inhibition of paracrine Hh signaling in
pancreatic stroma using SMO inhibitors [94–96]. Thus,
more thorough investigation of Hh activation and its
effect on angiogenesis is necessary.
Evading immunity
Although the human immune system is fully capable of
eliminating foreign matter and abnormal cells, cancer cells
evade the immune system through various mechanisms
[97]. Cancer cells can prevent T cell proliferation via up-
regulating toll like receptors [98], downregulating the
MHC molecules and antigens presented on their surface
[99], and immunoediting immune cells in their micro-
environment to promote cancer growth and survival. This
involves activating regulatory T cells and myeloid-derived
suppressor cells (MDSCs), which suppress anti-tumor im-
munity [100]. In recent years, several groups have reported
an emerging link between Hh signaling and the ability of
tumors to evade the immune system (Fig. 3). In patients
with BCC that were treated with vismodegib, there was
CD4 and CD8 T cell infiltration into the tumor with
concomitant upregulation of MHC class I molecules [101].
In T cells, Hh ligands activated IL-4, a cytokine responsible
for skewing T cells toward the Th2 phenotype. This T cell
sub-type enhances allergy reactions and suppresses im-
mune system surveillance thereby promoting tumor
growth [102]. JAK-STAT signaling is an extensive network
of molecules involved in developmental and reparative
functions such as cell proliferation, migration, and immune
system properties. IFNγ-activated STAT1 signaling induces
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apoptosis, halts progression through cell cycle and boosts
anti-tumor immunity. This signaling pathway is negatively
regulated by the suppressor of cytokine signaling (SOCS)
family of nine proteins. In keratinocytes and MB cells,
SOCS1 was found to be a direct target of GLI2, blocking
the IFN-γ/STAT1 pathway and inhibiting cell cycle arrest
and downregulating anti-tumor immunity [103]. Studies in
a GLI2 transgenic mouse showed significant reduction of
T cell activation which gave rise to impaired NF-κβ sig-
naling interfering with its normal function of activating
a pro-inflammatory immune cascade [104]. Though Hh
signaling seems to be connected to impaired T cell activa-
tion, some reports confirm Hh activation is linked cyto-
toxic T cell activation; this T cell-induced cytotoxicity was
abolished upon using SMO and GLI inhibitors [105]. This
dual activity is unsurprising for Hh signaling, as it is
important in T cell development [106], however, in the
presence of pathological conditions, the functions of the
pathway could shift. While the effects of Hh signaling on
macrophages are unknown, Hh signaling is evidently
involved in suppressing host immunity to promote tumor
growth by activating T regs, MDSCs, and the Th2 pheno-
type that promote angiogenesis and extracellular matrix
remodeling.
Resisting cell death
One of the most important mechanisms by which
cancers support their growth and immune system eva-
sion is through avoiding apoptosis [107, 108]. Apoptosis
is the programmed, self-destruction of cells that develop
structural damage beyond the capacity of DNA repair
machinery. The apoptotic pathway involves a family of
caspase proteins that lead to the formation of the
apoptosome; the BCL2 family of proteins inhibits this
process. In MM-derived cells, the tumor cells secrete
SHH; autocrine SHH signaling induces cell proliferation,
chemotherapy resistance, and protection against apop-
tosis by upregulating BCL2 [109]. Neutralizing anti-
bodies against SHH sensitized MM cells to apoptosis.
RNA analysis of clinical samples of GBM revealed
upregulated expression of GLI1 and PTCH1. vismodegib
treatment reduced GLI1 expression concomitant with
the induction of apoptosis and cell cycle arrest [110].
AKT (protein kinase B) promotes cell growth and
survival by inhibiting the pro-apoptotic function of the
BAD protein and inducing the NF-κβ pro-survival
pathway. In acute T-cell leukemia, GLI inhibition via
GANT-58 induced apoptosis and AKT-driven anti-
tumor responses [111]. In AML, GLI1 is overexpressed
and is considered a negative prognostic marker; its inhib-
ition reduced cell proliferation and induced apoptosis
[112]. In hepatocellular carcinoma, Hh signaling enhances
cell proliferation and therapy resistance. Inhibition of Smo
via cyclopamine in addition to radiation reduced cell sur-
vival and tumor size and induced DNA double stranded
breaks (DSB) [113]. By virtue of Hh signaling, abnormal
cancerous cells override death signals and continue to
grow uninterrupted, further enabling establishment of the
tumor mass.
Activating invasion and metastasis
The ability of tumor cells to metastasize is permitted
through the flexibility of the cells to alter their shape
and function, break through the basement membrane,
extravasate into lymph and blood vessels, and travel to
distant locations where they occupy a distinct micro-
environment [114, 115]. Several of these abilities are
modulated through the Hh pathway. SHH is highly cor-
related with aggressive disease stage in retinoblastoma,
progressively increasing as the disease advances to me-
tastasis [116]. In a renal cell carcinoma xenograft model,
Smo antagonism with Erismodegib inhibited prolifera-
tion, migration, invasive properties, and lung metastasis
Fig. 3 Emerging preliminary evidence implicates Hh signaling activation
in immune system suppression as a result of the pathway’s ability to
downregulate MHC I which suppresses cytotoxic T cell tumor
cell clearance, upregulate SOCS1 which inhibits STAT1 signaling,
and upregulate STAT6 which promotes T cell polarization toward
the Th2 phenotype. All three properties result in diminished
immune system function against tumors and the promotion
of pro-tumorigenic functions by T cells
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[117]. In ER-positive breast cancers, Gli1 promotes can-
cer stem cell (CSC)-like properties enhancing invasion
and EMT [118]. Also in breast cancer, IHH-induced
GLI1 activity promoted osteoblast expression of Rank
ligand and osteopontin (OPN). Both are vital molecules
involved in osteoclast activity, enabling dysregulated bone
remodeling that creates an osteolytic, pro-metastatic niche
in the bone tissue [119]. A similar increase of GLI1-
induced OPN was seen in human melanoma; an effect that
was abolished with SMO antagonist administration [120].
Hh signaling activation in thyroid CSCs was associated
with elevated expression of Gli1 and Snail and conse-
quently stimulated EMT associated with high numbers of
CSCs. Blocking Hh signaling induced the radiation sensi-
tivity of the tumor cells and decreased their self-renewal
activity [121]. A network modeling exercise study to
determine TGF-β–induced networks in several murine and
human hepatocellular cancer lines, revealed that TGF-β
induced EMTand lead to coupled activation of the Hh and
Wnt signaling pathways, further creating a network for
persistence of the EMT phenotype [122]. As a develop-
mental pathway, Hh signaling greatly influences cellular
differentiation and proliferation, therefore its potential in
promoting EMT is unsurprising. As such, Hh signaling
profoundly enhances the tumor cells’ ability to change their
phenotype and upregulate matrix proteases [90, 91]
cumulatively facilitating their movement and expansion
resulting in enriched invasive potential.
Hh signaling and cancer stem cells: Given the role of
Hh signaling during development when there is a dynamic
shift between cellular phenotypes from epithelial and mes-
enchymal type, it comes as no surprise that this is recapit-
ulated in cancer progression [123]. Staining of gastric
cancer patient samples and patient cell line derived-
xenografts showed that the CD44-expressing population
of stem-like cells overexpresses Hh proteins; consequently,
blocking Hh signaling with SMO inhibitor vismodegib
reduced the colony formation ability of these cells [124].
A more recent report again implicates SHH/GLI1 activa-
tion in gastric CSCs drug resistance; a function reversed
upon GLI and SMO inhibition by GANT61 and vismode-
gib treatments respectively [125]. Likewise, in colon
cancer, SMO antagonist cyclopamine reduced stem cell
marker expression and EMT in cell line spheroidal culture
[126]. p63, a key regulator in cell differentiation has been
shown to induce stem cell-like properties. In a breast
cancer model, tumor cell growth and self-renewal proper-
ties were modulated by p63-driven induction of Shh, Gli2,
and Ptch expression [37]. Also in pancreatic cancer, Hh
activity is strongly correlated with stem-like properties.
The novel approach of sulforaphane administration, a
cruciferous plant derivative shown to reduce inhibit stem
cell viability, inhibited SHH-driven activation and reduced
the expression of stem-cell pluripotency markers, Nanog
and Oct-4, and functionally reduced spheroid formation
[127]. Also in pancreatic cancer, blocking SHH signaling
with vismodegib or Gli1 and Gli2 silencing reduced the
viability of stem-like cells, decreased spheroid formation
and induced apoptosis [66]. The involvement of Hh
signaling in CSC sustenance promotes cancer resistance
to therapies through the induction of this stem-like state,
which are largely quiescent during the initial chemother-
apy treatments, then reactivating a recurring disease and
potential metastasis.
Genomic instability
The progression of cells through the cell cycle in order to
undergo replication requires the successful advancement
through many checkpoints which would suppress growth if
cells are experiencing chemical and physical stress or DNA
damage. Cancer cells though defective in structure and
function, employ different signaling pathways, including
the Hh pathway, to bypass those regulatory checkpoints
[128]. Aberrant Ptch1 and Sufu mutations in BCC associate
with abnormal cell cycle entry, cyclin D expression, in-
creased DNA damage, and impaired p53 expression. In
these cases cell cycling due to loss of cell cycle arrest and
progress through the G2/M checkpoint occurred inde-
pendently of p53 [129]. Recently, aberrant expression of
Gli1 in tumor cells showed to regulate tumor cell response
to replication blocks [130]. In these studies, Gli1 expression
has been shown to suppress replication stress in tumor
cells by regulating ATR mediated Chk1 phosphorylation
through transcriptional regulation of Bid. While Inhibition
of Gli1 in tumor cells reduced Bid levels and its association
with RPA-ATRIP complex leading to abrogation of ATR-
mediated Chk1 phosphorylation. Thus, inhibition of GLI1
in tumor cells sensitized them to chemotherapeutic agents
that target DNA Topoisomerase I [130]. A novel finding in
MB implicates upregulation of the co-receptor Boc in aber-
rant Hh activation in concert with Cyclin D1 and N-Myc
causing granule cell precursors to overproliferate and lead
to MB [68]. In keratinocytes, the GLI2-β isoform, which
lacks the N-terminal repressor domain, was found to
induce structural chromosomal abnormalities such as
chromosomal translocation, aneuploidy, and tetraploidy;
the overexpression of this N-terminal domain abolished
apoptosis and cell cycle checkpoint by decreasing 14-3-3s
(transcriptional target of p53) and CDK inhibitor p21
[131]. The capability of Hh signaling to bypass cell cycle
checkpoints maintains a constant activation in cellular
replicative programming, allowing even abnormal cells that
would normally cease to replicate to continue unrestricted
division and expansion.
Evading growth suppression
A possible mechanism by which tumors can evade cell
growth suppression other than cell cycle checkpoints is
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their ability to regulate autophagy. Autophagy is the
process by which cells get degraded and their compo-
nents recycled as a result of cellular stress or infections
[132]. In stressful conditions such as hypoxia, mitochon-
drial autophagy is induced by the activation of BNIP3
protein (BCL2 and adenovirus E1B 19 kDa-interacting
protein 3) and its induction of autophagosome forma-
tion. It can also result in cytochrome c and caspase
activation leading to apoptosis. Hh signaling has been
shown to downregulate this process in several biological
systems including cancer. Holla and colleagues have
shown that microorganisms including Mycobacteria,
Shigella, and Listeria downregulate the body’s autophagy
response by activating the Hh signaling pathway [133].
In non-small cell lung cancer (NSCLC), blocking SMO
and GLI1 induced autophagy and apoptotic responses
[134]. Furthermore, in pancreatic ductal adenocarcinoma
(PDAC) cells, blocking the activity of Gli proteins using
GANT-61 induced cell autophagy and reduced cell
viability [135]. Similar responses were seen in hepatocel-
lular carcinoma cells using GANT-61 characterized by
upregulation of Bnip3 [136]. Autophagy was the result
of Bnip3-driven displacement of the anti-apoptotic Bcl-2
from Beclin-1, the driver of autophagy. In chondrosar-
coma, Ihh expression is upregulated and associated with
increased Gli activity. Inhibition of Gli1 suppressed cell
proliferation through promoting cell cycle arrest, in-
duced apoptosis by downregulating Bcl2, and altered
mTOR phosphorylation culminating in autophagy [137].
Avoiding the normal suppressive signals that eliminate
infected or abnormal cells by virtue of dysregulated Hh
signaling promotes tumor cell growth and enhances the
potential to acquire and accumulate additional tumor
promoting mutations.
Hh signaling and therapy resistance – an important
feature of cancer recurrence
In addition to the impact of Hh signaling on profoundly
influencing several cancer processes, it also desensitizes
cancer to therapies. In breast cancer, the OPN oncopro-
tein was shown to activate non-classical Hh signaling
and GLI transcription, resulting in the upregulation of
multidrug resistance genes viz. ATP-binding cassette
transporters (ABCB1) and ATP-binding cassette sub-
family G member 2 (ABCG2). Treatment of cells with
GLI inhibitor GANT-61 or silencing GLI1 expression
abrogated this effect [138]. In prostate cancer, SHH
signaling promoted resistance to paclitaxel through the
overexpression of ABCB1 [139]. In castration-resistant
prostate cancer, patients develop resistance against the
normally used docetaxel treatment regimen. Combining
vismodegib Hh inhibitor with docetaxel significantly
reduced prostate cell proliferation, migration, and in-
duced apoptosis in vitro and in patient xenografts [140].
In a GBM model, miR-9-mediated downregulation of
PTCH1 resulted in the upregulation of Hh signaling and
resistance to the standard-of-care drug, temozolomide
that was reversed by treatment with the Smo inhibitor,
vismodegib [141]. Although vismodegib is generally
effective in BCC treatment, SMO point mutations can
prevent vismodegib binding thus giving rise to drug
resistance [142]. The formulation of a novel dual com-
pound NL-103 targeting both, mutant SMO and histone
deacetylases (HDAC) overcame vismodegib resistance.
By virtue of inhibiting HDACs, NL-103 downregulated
Smo and Gli2 [143]. Additionally in MM, SHH signaling
promoted resistance to chemotherapy-induced apoptosis,
which was reversed with the SHH blocking antibody 5E1.
In ovarian cancer, combining proteasome inhibitors with
Hh antagonist promoted paclitaxel sensitivity by reducing
drug resistance gene ABCB1 and promoting apoptosis
[144]. Erlotinib, an epidermal growth factor receptor-
tyrosine kinase inhibitor, is used for the treatment of
NSCLC, and patients often develop resistance against it
through inducing an EMT phenotype. Inhibiting Hh signal-
ing using vismodegib, sensitized NSCLC cells to Erlotinib
[145]. Hh signaling is strongly linked to chemotherapy
resistance in several cancer types as mentioned above;
therefore combination therapy using Hh inhibitors in
addition to standard of care cytotoxic chemotherapies will
greatly improve patient response and potentially signifi-
cantly enhance survival.
Hh signaling also desensitizes tumor cells to radiother-
apy. In hepatocellular carcinoma, SHH-driven signaling
induced PTCH1 and Gli1 expression; this protected cells
against ionizing radiation (IR) [146]. The use of an
antibody to neutralize SHH ligands or a GLI1 silencing
approach reversed this protective capability. In GBM,
Shh signaling was activated upon IR treatment [147].
Additionally, cyclopamine treatment increased DNA
DSB as indicated by the induction of H2AX, a histone
family member that becomes phosphorylated upon DNA
breaks. In colon cancer, radiation therapy resistance was
abolished upon treating cells with GLI inhibitor GANT-
61 concomitant with detection of DNA aberrations as
indicated by induced H2AX and apoptosis as indicated
by caspase 3 [148]. Therefore, there is direct evidence
for the involvement of Hh activation and protection
against DSB; effects that are reversed with Hh blockade
at different stages: antibody ligand blocking, Smo inhib-
ition, or Gli1 silencing.
Conclusion
It is evident from the presented compilation of literature
that the Hh signaling pathway is extensively studied and
significantly linked to several cancer types. Aberrations in
almost all molecular members of the pathway have been
reported across multiple malignancies. The pathway’s
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ability to promote replicative immortality, evade genomic
instability and growth suppression, sustain proliferative
signaling, and switch cellular energetics are crucial for the
tumor cells’ ability to grow uncontrollably, avoiding mul-
tiple levels of homeostatic cellular regulation that prevent
damaged cells from surviving. As the tumors establish in
their niche, they employ Hh signaling to induce angiogen-
esis, take advantage of tumor promoting inflammation
and escape immune system surveillance to facilitate tissue
invasion and metastasis.
In closing, Hh signaling is activated across multiple can-
cer types in many different ways: through mutations or
through non-classical ligand-independent or through non-
canonical modes. Hh signaling influences every aspect of a
tumor cell: initiation, establishment and its metastatic
journey. With the promising success of inhibitors of this
pathway in the clinic, the pathway continues to offer the
scope to direct and design inhibitors to function at
multiple levels. At present, a large cadre of chemically
modified pharmacological inhibitors has been developed
to target SMO. In order to pursue the elimination of the
rapidly-evolving tumor and its associated milieu, it is
necessary to continue efforts to target this pathway at all
levels. Avenues to target and block the activity of ligands,
block co-receptors Boc, Cdo, and Gas1 and interfere with
the activity of GLI transcription factors are currently being
explored by many laboratories. Discovered in the Derris
glabrescens plant, Glabrescione B is among the newly
identified, naturally occurring small molecule inhibitor,
functioning in a similar mechanism to GLI inhibitors
GANT-58 and 61 [149]. The recent characterization that
the bromodomain and extra terminal domain (BET) mem-
ber BRD4 protein can bring about activation of Hh/GLI
signaling by upregulating the expression of GLI proteins,
has brought to the forefront the promising use of the
small molecule BRD4 inhibitor JQ1, to abolish dysregu-
lated signaling in tumors that bear oncogenic SMO
mutations [150]. With the knowledge of non-canonical
Hh signaling, efforts need to be directed towards the
discovery and development of small molecules that can
interfere in this process in order to effectively eliminate
resistant populations.
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